IMNN — Imunon, Inc.

Summary of Imunon's Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: As of December 31, 2025, Imunon reported cash and cash equivalents of $8.8 million, reflecting disciplined cash management and proceeds from warrant exercises and ATM usage.
• Expenses: Research and development expenses for 2025 were $7.8 million, significantly lower than in 2024 due to the completion of the OVATION 2 study and focused spending on the OVATION 3 study.
• Net Loss: The net loss for 2025 was $14.5 million ($6.83 per share), an improvement from $18.6 million ($16.94 per share) in 2024, attributed to cost discipline.
• Stock Adjustments: All share amounts reflect a 15-for-1 reverse stock split effective July 2025 and a 15% stock dividend declared in Q3 2025.

2. Strategic Updates and Business Highlights:

• OVATION 3 Trial: The pivotal Phase III trial for IMNN-001 is progressing well, with enrollment ahead of plan and strong interest from clinical sites. The trial is designed to confirm the promising results from the Phase II OVATION 2 study, which showed a median overall survival benefit of 14.7 months.
• Clinical Data Presentation: The company showcased its Phase II data at major scientific forums, enhancing visibility and interest in its clinical programs.
• Partnership Opportunities: There is ongoing interest in potential partnerships for IMNN-001 and the TheraPlas technology platform, with new inquiries following the recent positive data release.

3. Forward Guidance and Outlook:

• Enrollment Goals: Imunon aims to enroll approximately 80 patients in the OVATION 3 trial within the next 12 months, with full enrollment expected by 2029.
• Regulatory Pathway: The company is optimistic about the regulatory approval process, bolstered by FDA endorsement of overall survival as the primary endpoint for the Phase III trial.
• Financial Strategy: Imunon is focused on securing long-term investors while managing its cash runway prudently, with expectations to extend operational funds into the second half of 2026.

4. Bad News, Challenges, or Points of Concern:

• Market Conditions: The company is navigating a challenging capital markets environment, which may impact its financing strategy and ability to secure investments.
• Dependence on Trial Success: The future value creation is heavily reliant on the successful outcomes of the OVATION 3 trial, which carries inherent risks associated with clinical trials.
• Competitive Landscape: The potential emergence of new therapies in the ovarian cancer treatment space could influence the standard of care and impact patient enrollment and treatment dynamics.

5. Notable Q&A Insights:

• FDA Engagement: Imunon has not yet presented the final OVATION 2 data to the FDA but plans to do so, particularly regarding the PARP inhibitor patient population.
• Interim Analysis Plans: The first interim analysis of the OVATION 3 trial is expected about a year after full enrollment, with the potential for expedited regulatory action if results are favorable.
• Partnership Environment: The recent positive data has sparked renewed interest from potential partners, although the company emphasizes that strategic fit and timing are critical.
• MRD Study Insights: While OVATION 2 will not provide MRD data, ongoing studies may yield insights into minimal residual disease and its implications for treatment outcomes in ovarian cancer.

Overall, Imunon is positioned for significant milestones in 2026, driven by strong clinical data and strategic focus on its lead product, IMNN-001, despite facing challenges in financing and market competition.